Details of the Drug Reposition

General Information of This Drug (ID: DMG5Q7F)

• Drug Name: IPI-549 (DMG5Q7F)
• Synonyms: XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((

Information on Drug Reposition of This Drug

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bladder cancer	DISUHNM0	2C94	Phase 2	[1]

6 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1	[2]
Melanoma	DIS1RRCY	2C30	Phase 1	[2]
Mesothelioma	DISKWK9M	2C51.2	Phase 1	[2]
Breast cancer	DIS7DPX1	2C60-2C65	Phase 1	[2]
Adrenocortical carcinoma	DISZF4HX	2D11.Z	Phase 1	[2]
Head and neck cancer	DISBPSQZ	2D42	Phase 1	[2]

References

• [1] ClinicalTrials.gov (NCT03980041) Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)